Research Analysts Issue Forecasts for Epizyme Inc’s Q3 2018 Earnings (EPZM)

Epizyme Inc (NASDAQ:EPZM) – Investment analysts at Leerink Swann issued their Q3 2018 earnings per share (EPS) estimates for Epizyme in a research note issued on Monday. Leerink Swann analyst G. Porges anticipates that the biopharmaceutical company will post earnings of ($0.90) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $22.00 target price on the stock.

Other equities analysts have also recently issued reports about the company. Morgan Stanley began coverage on Epizyme in a research note on Wednesday, January 10th. They set an “overweight” rating and a $20.00 price objective on the stock. Oppenheimer set a $26.00 price objective on Epizyme and gave the stock a “buy” rating in a research note on Tuesday, December 12th. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Epizyme in a research note on Thursday, November 2nd. Finally, Royal Bank of Canada cut Epizyme from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $20.00 to $16.00 in a research note on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. Epizyme has an average rating of “Buy” and a consensus target price of $22.73.

Epizyme (NASDAQ EPZM) opened at $16.20 on Wednesday. Epizyme has a one year low of $9.30 and a one year high of $20.45.

Institutional investors and hedge funds have recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its holdings in Epizyme by 3.3% during the second quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock worth $501,000 after acquiring an additional 1,068 shares during the period. California Public Employees Retirement System boosted its position in shares of Epizyme by 2.2% in the 2nd quarter. California Public Employees Retirement System now owns 135,500 shares of the biopharmaceutical company’s stock valued at $2,046,000 after purchasing an additional 2,900 shares during the period. Teachers Advisors LLC boosted its position in shares of Epizyme by 5.8% in the 2nd quarter. Teachers Advisors LLC now owns 73,952 shares of the biopharmaceutical company’s stock valued at $1,117,000 after purchasing an additional 4,030 shares during the period. Alps Advisors Inc. boosted its position in shares of Epizyme by 9.1% in the 3rd quarter. Alps Advisors Inc. now owns 57,472 shares of the biopharmaceutical company’s stock valued at $1,095,000 after purchasing an additional 4,797 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Epizyme by 2.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 202,178 shares of the biopharmaceutical company’s stock valued at $3,852,000 after purchasing an additional 5,140 shares during the period. 86.04% of the stock is currently owned by institutional investors.

In other news, COO Matthew Ros sold 72,264 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $16.63, for a total transaction of $1,201,750.32. Following the transaction, the chief operating officer now directly owns 74,867 shares of the company’s stock, valued at $1,245,038.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 25.20% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/07/research-analysts-issue-forecasts-for-epizyme-incs-q3-2018-earnings-epzm.html.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply